<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html>
<head>
<title>ATHERO-FLUX</title>
<meta name="description" content="Targeting novel lipid pathways for treatment of cardiovascular disease">
<meta name="keywords" content="novel, clipid, pathways, treatment, cardiovascular, disease">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1" />
<style type="text/css" media="all">
@import "css/style.css";
</style>
</head>
<body>
<div class="content">
  <div id="toph"></div>
  <div id="header">
    <div class="rside">
      <div class="logo"><img src="images/logo.png" width="350" height="143" alt="logo" /></div>
    </div>
    <div class="lside">
      <div class="title">
        <h2 style="font-family: Tahoma, Geneva, sans-serif; font-size: 130%;">ATHERO-FLUX</h2>
        <strong>Targeting novel lipid<br />
        pathways for treatment<br />
        of cardiovascular disease</strong><br />
      </div>
    </div>
  </div>
  <div id="main">
    <div class="center">
      <h2>Project abstract</h2>
      <br />
      <div class="img"><img src="images/heart.jpg" alt="heart" /></div>
      <p class="clear_text">Lipid  lowering has significantly reduced <strong>cardiovascular  disease</strong> (CVD) mortality in EU. However, the aim to abolish  CVD in EU is far from achieved and attempts to improve on the benefits of  statins with new agents have not yet delivered new therapeutics. The Consortium<strong> Athero-Flux</strong> builds on FP7-generated  large-scale <strong>lipidomics data</strong> showing  that specific <strong>sphingolipids (SLs) </strong>with  specific acyl chain lengths are better predictors of CV outcome than  traditional risk factors such as low-density lipoprotein-cholesterol.<br />
        <br />
        SLs  are implicated in significant biological activities including cell survival,  inflammation, and metabolic&nbsp; diseases.  Moreover, their levels in metabolic diseases are modulated by previously  unrecognized factors such as the gut microflora. Thus, we hypothesize that by  controlling <strong>SL metabolism</strong> a better  primary and secondary prevention of CVD events than with statins alone can be  achieved.<br />
        <br />
        <strong>Athero-Flux</strong> builds on cutting-edge <strong>SME-led biotechnological tools</strong> including: a) high-throughput  lipidomic platforms that allow the study of kinetics of lipid metabolism at the  molecular lipid level including the new stable isotope labelling technique  (Flux); b) whole genome RNA interference screening tools that will allow to  identify the regulators of the production of SLs and the mediators of their  biological effect; c) unique locked nucleotide antagonist platforms that have  been successfully used clinically in more than 300 patients worldwide. The  identification and the validation of the best targets to <strong>abate SL metabolism</strong> though a combination of SME-based leading technology  and academia modeling has a strong potential for <strong>development of new lipid lowering therapeutics</strong> to abate previously  unrecognized risk factors for CVD. </p>
      <p>&nbsp;</p>
      <p>&nbsp;</p>
      <p>&nbsp;</p>
      <p>&nbsp;</p>
      <p>&nbsp;</p>
      <table border="0" align="center" cellpadding="0" cellspacing="0">
        <tr>
          <td width="130" valign="middle"><span class="padding"><img src="images/7fp.jpg" width="100" height="72" alt="7fp" /></span></td>
          <td valign="middle"><span class="padding"><img src="images/eu-flag.jpg" width="100" height="67" alt="eu-flag" /></span></td>
        </tr>
      </table>
      <p>&nbsp;</p>
      <p align="center"><em>This project is supported  through Coordination Theme 1 (Health) of the<br />
        European Community's FP7. Grant  agreement number</em><em> <em>HEALTH-F2-2013-602222</em></em> </p>
      <p>&nbsp;</p>
      <p>&nbsp;</p>
      <p>&nbsp;</p>
    </div>
    <div class="leftmenu">
      <div class="nav">
        <ul>
          <li><a href="#">Home</a></li>
          <li><a href="project.html">Project info</a></li>
          <li><a href="structure.html">Structure</a></li>
          <li><a href="objectives.html">Objectives</a></li>
          <li><a href="participants.html">Participants</a></li>
          <li><a href="press_release.html">Press release</a></li>
          <li><a href="publications.html">Publications</a></li>
          <li><a href="meetings.html">Meetings</a></li>
          <li><a href="reserved/login.asp">Reserved area</a></li>
        </ul>
      </div>
      <div class="padding">
        <hr />
        <br />
        <h2>News</h2>
        <h3>NEWS AND EVENTS</h3>
        <br />
        <marquee behavior="slide" direction="up" height="300" scrollamount="15">
        <p style="font-size:11px;"><strong>November 2015</strong><br />
          <strong><a href="meetings.html">Annual meeting, Athens,<br />
          3-4 November 2015</a></strong><br />
          <br />
        </p>
        <table border="0" cellspacing="0" cellpadding="0">
          <tbody>
            <tr>
              <td width="25"><a href="documents/AF_Agenda_2015.pdf" target="_blank"><img src="images/pdf.png" width="16" height="16" alt=""/></a></td>
              <td><a href="documents/AF_Agenda_2015.pdf" target="_blank">download the agenda</a></td>
            </tr>
          </tbody>
        </table>
        <br />
        <br />
        <p style="font-size:11px;"><strong>September 2014</strong><br />
          <strong><a href="meetings.html">AtheroFlux annual meeting<br />
          21-23 September, Siena</a></strong><br />
          <br />
          <img src="images/arrow.gif" width="7" height="7" alt=""/> <strong><a href="http://www.altaweb.it/galleries/abf2014/login.php" target="_blank" style="font-size: 13px">see the web gallery </a></strong><br />
          <br />
        </p>
        <br />
        <p style="font-size:11px;"><strong>March 2014</strong><br />
          Athero-Flux website is online.</p>
        </marquee>
        <br />
        <br />
        <hr />
        <br />
        <marquee behavior="slide" direction="up" height="500" scrollamount="10">
        <h2>Project info</h2>
        <p>&nbsp;</p>
        <table border="0" cellspacing="0" cellpadding="0">
          <tbody>
            <tr>
              <td width="20"><a href="documents/AF_Brochure.pdf" target="_blank" title="download pdf file"><img src="images/pdf.png" width="16" height="16" alt="pdf"/></a></td>
              <td><strong><a href="documents/AF_Brochure.pdf" target="_blank">Download the brochure</a></strong></td>
            </tr>
          </tbody>
        </table>
        <p>&nbsp;</p>
        <p style="font-size:11px; line-height: 1.7em;"><strong>Acronym</strong>: <span style="font-size:11px;">Athero-Flux</span><br />
          <strong>EC Contribution</strong>: &euro; 5.987.700<br />
          <strong>Duration</strong>: 60 months<br />
          <strong>Starting date</strong>:
          01/09/2013<br />
          <strong>Instrument</strong>: 
          Collaborative project<br />
          <strong><br />
          Coordinator</strong>:<br />
          The Chancellor, Masters and Scholars of the University of Oxford<br />
          <a href="mailto:#" target="_blank">Prof Marc Feldmann </a><br />
          Head, Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford,<br />
          Roosevelt Drive<br />
          Headington Oxford, OX3 7FY Tel: +44 (0)1865-612611<br />
          Fax: +44 (0)1865-612621</p>
        </marquee>
        <br />
        <br />
        <br />
        <p style="font-size:11px;"><em>Last update: 27/10/2015</em></p>
      </div>
    </div>
  </div>
  <br />
  &nbsp;<br />
  <div id="footer">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &copy; 2014 Athero-Flux - all rights reserved | powered by <a href="http://www.altaweb.eu" target="_blank">ALTA</a></div>
</div>
</body>
</html>
